Frazier Lifesciences Acquisition Corporation Stock

FLAC

KYG3710A1058

Latest news: Frazier Lifesciences Acquisition Corporation

22-11-23	Frazier Lifesciences Acquisition Corporation Announces Executive Changes	CI
22-11-22	Frazier Lifesciences Acquisition Corporation(NasdaqCM:FLAC) dropped from NASDAQ Composite Index	CI
22-11-21	NewAmsterdam Pharma B.V. completed the acquisition of Frazier Lifesciences Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI
22-11-15	Frazier Lifesciences Shareholders Approve Merger With NewAmsterdam Pharma Holding	MT
22-11-09	Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-11	Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-07-25	NewAmsterdam Pharma to Go Public in Deal With Frazier Lifesciences SPAC	MT
22-07-24	NewAmsterdam Pharma B.V. entered into a definitive business combination agreement to acquire Frazier Lifesciences Acquisition Corporation from a group of shareholders for approximately $490 million.	CI
22-07-20	Frazier Lifesciences Acquisition Negotiates Business Combination With NewAmsterdam Pharma	MT
22-05-12	Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-03-25	Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-24	Frazier Lifesciences Acquisition Corporation Auditor Raises 'Going Concern' Doubt	CI
21-06-05	Certain Class B Ordinary Shares of Frazier Lifesciences Acquisition Corporation are subject to a Lock-Up Agreement Ending on 6-JUN-2021.	CI

More news

Press Releases: Frazier Lifesciences Acquisition Corporation

22-11-24	NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib	AQ
22-11-23	NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients	AQ
22-11-16	Frazier Lifesciences Acquisition Corporation shareholders approve business combination with NewAmsterdam Pharma Holding B.V	AQ
22-11-15	FRAZIER LIFESCIENCES ACQUISITION CORP : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
22-11-15	Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.	BU

More press releases

Frazier Lifesciences Acquisition Corporation is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It intends to identify opportunities in the biotechnology sector. It has conducted no operations and has generated no revenues.

Employees

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/22/22	David Topper	Exercice	Chief Financial Officer	30,000	0.8696%
11/22/22	Krishna R. Polu	Exercice	Director	30,000	0.8696%
11/22/22	Michael Bigham	Exercice	Director	30,000	0.8696%

Frazier Lifesciences Acquisition Corporation Stock

Stocks

FLAC

KYG3710A1058

Latest news: Frazier Lifesciences Acquisition Corporation

Press Releases: Frazier Lifesciences Acquisition Corporation

Quotes and Performance

Latest insider transactions

Company Profile